Factor IX Antibody (13B9): sc-80601
- Factor IX Antibody (13B9) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against full length native Factor IX of human origin
- recommended for detection of native Factor IX of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Factor IX Antibody (13B9). This work is in progress.
QUICK LINKS
SEE ALSO...
Factor IX Antibody (13B9) is a mouse monoclonal IgG1 antibody that detects coagulation factor IX in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Factor IX, also known as plasma thromboplastic component, plays a crucial role in the blood coagulation cascade, which is essential for hemostasis following tissue injury. This vitamin K-dependent serine protease is synthesized in the liver and circulates as an inactive precursor until activated by factor XIa-mediated proteolytic cleavage, resulting in factor IXa. The active form consists of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, which are linked by disulfide bonds, highlighting the importance of structural integrity for function. Disruptions in the Factor IX gene, such as point mutations or deletions, can lead to hemophilia B, a serious bleeding disorder that underscores the significance of Factor IX in maintaining normal blood clotting. Factor IX (13B9) antibody is an invaluable tool for researchers studying coagulation pathways and related disorders, providing insights into molecular mechanisms underlying hemostatic function and potential therapeutic targets.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Factor IX Antibody (13B9) References:
- Factor VIII and factor IX inhibitors in haemophiliacs. | Ljung, R., et al. 1992. Lancet. 339: 1550. PMID: 1351234
- Creation of a mouse expressing defective human factor IX. | Jin, DY., et al. 2004. Blood. 104: 1733-9. PMID: 15178576
- Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy. | Brooks, AR., et al. 2013. J Thromb Haemost. 11: 1699-706. PMID: 23692404
- Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. | Powell, J., et al. 2015. Br J Haematol. 168: 113-23. PMID: 25209873
- The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa. | Liebman, HA., et al. 1987. J Biol Chem. 262: 7605-12. PMID: 3108254
- Factor-IX deficiency in the nephrotic syndrome. | Handley, DA. and Lawrence, JR. 1967. Lancet. 1: 1079-81. PMID: 4164772
- Further evaluation of a heparin neutralizer and its effect on factor IX in normal and coumadin-plasma. | Vargo, JJ. and Joist, JH. 1983. Thromb Res. 29: 281-8. PMID: 6845282
- Activation of factor IX by factor XIa--a spectrophotometric assay for factor IX in human plasma. | Tans, G., et al. 1982. Thromb Haemost. 48: 127-32. PMID: 6983739
- Epitope mapping of human factor IX inhibitor antibodies. | Takahashi, I., et al. 1994. Br J Haematol. 88: 166-73. PMID: 7528527
- Factor IX antigen by radioimmunoassay in heterozygotes for hemophilia B. | Thompson, AR. 1977. Thromb Res. 11: 193-203. PMID: 905971
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor IX Antibody (13B9) | sc-80601 | 100 µg/ml | $316.00 |